‘Caged’ or stage 4 melanoma, dangerous skin cancers with a high risk of recurrence, has in past years become more and more deadly. Data shows that the vast majority of students become infected and several have died, yet many (10-40%) survivor of earlier stages of disease. The killers’ numbers are determined by either the present or past use of a red, red:purple, purple:black patch containing either Extracellular Luminescent DNA (ELP) or patient-derived antigens. The ELP layer is DNA that is carried by cells. Once inside the cell, it slips out from the membrane, some 15 μm in, and subverts the relationship of DNA and immune cells. ELP has been present in nearly all forms of human skin cancer with the highest incidence in the skin immunotherapy field. ELP is also implicated to form large numbers of circulating tumor cells, thus essentially allowing the killer cells to both overcome and bolster immunity against infections. The idea for the ELP layer appeared in routine drug research in the 1990s, and the concept has gone on to establish vast eradication programs for MEN and other skin cancer types. Elsewhere, offensive skin tumours are also a deadly concern for physicians.
The problem, as with many other diseases plaguing men, is that a short-term immunotherapy regimen—usually NK+ chemotherapy (C-beta-methyl-10-15 pO-CT) —is ineffective against certain forms of skin cancer. Elk-dermatologists, dermatologists, and dermatological oncologists struggle to find a routine, standardized therapy, and keep patients on it for any decent return from chemotherapy. After breast cancer and colorectal cancer, skin cancer is only diagnosed during several weeks. Although most patients respond well to treatment, melanoma tumors can soar in incidence and survival rates.
It has long been suggested by numerous researchers, and other physicians, that treatment of melanoma can be intensified by limiting tumor cell numbers. A recent study published in Science Translational Medicine points to the ELP layer, suggesting an INSIDER treatment for metastatic melanoma, if not fully eradicated, can be effective.
A parallel set of new research findings suggests that combining ELP treatment with other antigens in the skin, such as free histocompatibility proteins, may also be effective. About 40% to 60% of skin cancer patients eventually succumb to the disease and this may be the result of immune infiltration. In some cases, patients are treated with histocompatible drugs that are effective against the skin cancer. With such a combination in place, some dangerous skin cancers appear virtually eliminated, yet statistical evidence of recurrences suggest a higher recurrence rate than in those patients who were treated with the chemotherapy-like drug combination alone. It is virtually certain that silencing immunity and/or virtually eradicating the gene responsible for the blood-brain barrier will boost the effectiveness of the EGFR/EGFR inhibitor combination.
The study evidences the possibility of combined ELP and second-generation EGFR inhibitor therapy in melanomas and the need to be investigated in larger studies. “If drugs act primarily in the erogenous zone of the skin, the EGFR inhibitor would be a better choice than ELP for cells that are still resistant.” explains Laer-McDermid.
